<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28732070</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Characterization of human enterovirus71 virus-like particles used for vaccine antigens.</ArticleTitle><Pagination><StartPage>e0181182</StartPage><MedlinePgn>e0181182</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0181182</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0181182</ELocationID><Abstract><AbstractText>Human enterovirus 71 (EV71) is a major causative pathogen of hand, foot and mouth disease (HFMD) and has caused outbreaks with significant mortality among young children in the Asia-Pacific region in recent years. Towards developing a vaccine for this disease, we have expressed and purified EV71 virus-like particles (VLPs), which resemble the authentic virus in appearance, capsid structure and protein sequence, from insect cells (Sf9) using a multistep chromatography process. We demonstrated intracellular localization of the VLPs in host cells by in situ immunogold detection, electron microscopy and immunofluorescence. Characteristics of these EV71 VLPs were studied using a variety of immunological and physicochemical techniques, which aimed to reveal that the purified EV71 VLPs have good morphology and structure consistent with natural EV71 empty capsids. Results of the amino acid analysis, SDS-PAGE, Western blotting and high-performance liquid chromatography confirmed the high purity of the EV71 VLPs. However the sedimentation coefficient of the VLPs showed that they were smaller than that of secreted EV71 VLPs purified by discontinuous cesium chloride density gradients, they were similar to the empty capsids of natural EV71 virions reported previously. Combined with the previous study that EV71 VLPs purified by a multistep chromatography process were able to elicit strong humoral immune responses in mice, our results further supported the conclusion that our EV71 VLPs had well-preserved molecular and structural characteristics. The EV71 VLPs produced from the baculovirus expression system and purified by a multistep chromatography process displayed key structural and immunological features, which would contribute to their efficacy as a HFMD vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Dandan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Sciences, Jilin Agricultural University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Shiyang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Beijing Proteome Research Center, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chuntian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dawei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Changchun BCHT Biotechnology Company, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Yanfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Changchun BCHT Biotechnology Company, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Youlei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Changchun BCHT Biotechnology Company, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Changchun BCHT Biotechnology Company, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yongge</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Weiheng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Linjun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Chunlai</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0464-7226</Identifier><AffiliationInfo><Affiliation>National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067493" MajorTopicYN="N">Dynamic Light Scattering</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018625" MajorTopicYN="N">Microscopy, Atomic Force</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061987" MajorTopicYN="N">Sf9 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28732070</ArticleId><ArticleId IdType="pmc">PMC5521781</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0181182</ArticleId><ArticleId IdType="pii">PONE-D-17-00491</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, et al.
Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis. 2000;31(3):678&#x2013;83. doi: 10.1086/314032 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314032</ArticleId><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma E, Chan KC, Cheng P, Wong C, Chuang SK. The enterovirus 71 epidemic in 2008&#x2014;public health implications for Hong Kong. Int J Infect Dis. 2010;14(9):e775&#x2013;80. doi: 10.1016/j.ijid.2010.02.2265 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.02.2265</ArticleId><ArticleId IdType="pubmed">20599410</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26(1):91&#x2013;107. .</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778&#x2013;90. doi: 10.1016/S1473-3099(10)70194-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, Lu J, Kung HF, He ML. The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol. 2011;37(4):313&#x2013;27. doi: 10.3109/1040841X.2011.580723 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1040841X.2011.580723</ArticleId><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, et al.
An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7:94
doi: 10.1186/1743-422X-7-94 ; PubMed Central PMCID: PMCPMC2885340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Cao Z, Zeng DD, Wang Q, Wang X, Qian H. Epidemiological analysis, detection, and comparison of space-time patterns of Beijing hand-foot-mouth disease (2008&#x2013;2012). PLoS One. 2014;9(3):e92745
doi: 10.1371/journal.pone.0092745 ; PubMed Central PMCID: PMCPMC3963949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0092745</ArticleId><ArticleId IdType="pmc">PMC3963949</ArticleId><ArticleId IdType="pubmed">24663329</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan XF, Gao S, Xia JF, Ye R, Yu H, Long JE. Epidemic characteristics of hand, foot, and mouth disease in Shanghai from 2009 to 2010: Enterovirus 71 subgenotype C4 as the primary causative agent and a high incidence of mixed infections with coxsackievirus A16. Scand J Infect Dis. 2012;44(4):297&#x2013;305. doi: 10.3109/00365548.2011.634433 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365548.2011.634433</ArticleId><ArticleId IdType="pubmed">22176514</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin XG, Yi HX, Shu J, Wang XJ, Wu XJ, Yu LH. Clinical and epidemiological characteristics of adult hand, foot, and mouth disease in northern Zhejiang, China, May 2008-November 2013. BMC Infect Dis. 2014;14:251
doi: 10.1186/1471-2334-14-251 ; PubMed Central PMCID: PMCPMC4026826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-251</ArticleId><ArticleId IdType="pmc">PMC4026826</ArticleId><ArticleId IdType="pubmed">24885052</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, et al.
Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother. 2013;9(8):1701&#x2013;5. doi: 10.4161/hv.24949 ; PubMed Central PMCID: PMCPMC3906269.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al.
Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024&#x2013;32. doi: 10.1016/S0140-6736(13)61049-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, et al.
An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007;81(17):9386&#x2013;95. doi: 10.1128/JVI.02856-06 ; PubMed Central PMCID: PMCPMC1951441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31(32):3281&#x2013;7. doi: 10.1016/j.vaccine.2013.05.019 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, et al.
Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30(7):1305&#x2013;12. doi: 10.1016/j.vaccine.2011.12.081 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20(5&#x2013;6):895&#x2013;904. .</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K, Poh CL, Fecondo J, Pourianfar H, Shaw J, Grollo L. Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach. Vaccine. 2012;30(49):7105&#x2013;10. doi: 10.1016/j.vaccine.2012.09.030 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.030</ArticleId><ArticleId IdType="pubmed">23022400</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, et al.
Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29(26):4362&#x2013;72. doi: 10.1016/j.vaccine.2011.04.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, et al.
Expression, purification and charaterization of enterovirus-71 virus-like particles. World J Gastroenterol
2006;12(6):921&#x2013;7. PubMed Central PMCID: PMCPMC4066158. doi: 10.3748/wjg.v12.i6.921
</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i6.921</ArticleId><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, et al.
Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26(15):1855&#x2013;62. doi: 10.1016/j.vaccine.2008.01.058
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Jiang L, Liang Z, Mao Q, Su W, Zhang H, et al.
Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice. Hum Vaccin Immunother. 2014;10(10):2885&#x2013;95. doi: 10.4161/hv.29823 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.29823</ArticleId><ArticleId IdType="pmc">PMC5443096</ArticleId><ArticleId IdType="pubmed">25483672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D, Sun B, Jiang H, Sun S, Kong FT, Ma Y, et al.
Enterovirus71 virus-like particles produced from insect cells and purified by multistep chromatography elicit strong humoral immune responses in mice. J Appl Microbiol. 2015;119(4):1196&#x2013;205. doi: 10.1111/jam.12922 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jam.12922</ArticleId><ArticleId IdType="pubmed">26248815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Gao F, Mao Q, Shao J, Jiang L, Liu D, et al.
Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice. Hum Vaccin Immunother. 2015;11(10):2406&#x2013;13. doi: 10.1080/21645515.2015.1053675 ; PubMed Central PMCID: PMCPMC4635907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1053675</ArticleId><ArticleId IdType="pmc">PMC4635907</ArticleId><ArticleId IdType="pubmed">26036916</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong M, Zhu H, Zhou J, Yang C, Feng J, Huang X, et al.
Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development. J Virol. 2014;88(11):6444&#x2013;52. doi: 10.1128/JVI.00200-14 ; PubMed Central PMCID: PMCPMC4093858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00200-14</ArticleId><ArticleId IdType="pmc">PMC4093858</ArticleId><ArticleId IdType="pubmed">24672036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, et al.
A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19(4):424&#x2013;9. doi: 10.1038/nsmb.2255 ; PubMed Central PMCID: PMCPMC3378640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschuyteneer M, Elouahabi A, Plainchamp D, Plisnier M, Soete D, Corazza Y, et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccin. 2010;6(5):407&#x2013;19. .</Citation><ArticleIdList><ArticleId IdType="pubmed">20953154</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Allen MJ, Wang Y, Wang B, Wang N, Shi L, et al.
Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine. 2012;8(7):1182&#x2013;9. doi: 10.1016/j.nano.2012.01.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2012.01.007</ArticleId><ArticleId IdType="pubmed">22306156</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbonnelle E, Mesquita C, Bille E, Day N, Dauphin B, Beretti J-L, et al.
MALDI-TOF mass spectrometry tools for bacterial identification in clinical microbiology laboratory. Clinical Biochemistry. 2011;44(1):104&#x2013;9. doi: 10.1016/j.clinbiochem.2010.06.017
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2010.06.017</ArticleId><ArticleId IdType="pubmed">20620134</ArticleId></ArticleIdList></Reference><Reference><Citation>Bantscheff M, Lemeer S, Savitski MM, Kuster B. Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Analytical and Bioanalytical Chemistry. 2012;404(4):939&#x2013;65. doi: 10.1007/s00216-012-6203-4
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-012-6203-4</ArticleId><ArticleId IdType="pubmed">22772140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotoh T, Fukuhara M, Kikuchi K-I. Mathematical model for change in diameter distribution of baculovirus-infected Sf-9 insect cells. Biochemical Engineering Journal. 2008;40(2):379&#x2013;86. doi: 10.1016/j.bej.2008.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bej.2008.01.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrmann GF. Baculovirus Molecular Biology. 3rd ed. Bethesda (MD)2013.</Citation></Reference><Reference><Citation>Ku Z, Liu Q, Ye X, Cai Y, Wang X, Shi J, et al.
A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014;32(34):4296&#x2013;303. doi: 10.1016/j.vaccine.2014.06.025 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.06.025</ArticleId><ArticleId IdType="pubmed">24950363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SY, Chung YC, Chiu HY, Chi WK, Chiang BL, Hu YC. Evaluation of the stability of enterovirus 71 virus-like particle. J Biosci Bioeng. 2014;117(3):366&#x2013;71. doi: 10.1016/j.jbiosc.2013.08.015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiosc.2013.08.015</ArticleId><ArticleId IdType="pubmed">24140131</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L, Sanyal G, Ni A, Luo Z, Doshna S, Wang B, et al.
Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci. 2005;94(7):1538&#x2013;51. doi: 10.1002/jps.20377 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.20377</ArticleId><ArticleId IdType="pubmed">15929070</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy HC, Bostina M, Filman DJ, Hogle JM. Catching a virus in the act of RNA release: a novel poliovirus uncoating intermediate characterized by cryo-electron microscopy. J Virol. 2010;84(9):4426&#x2013;41. doi: 10.1128/JVI.02393-09 ; PubMed Central PMCID: PMCPMC2863768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02393-09</ArticleId><ArticleId IdType="pmc">PMC2863768</ArticleId><ArticleId IdType="pubmed">20181687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K, He YL, Li HY, Chen R. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease. J Virol. 2015;89(12):6196&#x2013;208. doi: 10.1128/JVI.00422-15 ; PubMed Central PMCID: PMCPMC4474312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00422-15</ArticleId><ArticleId IdType="pmc">PMC4474312</ArticleId><ArticleId IdType="pubmed">25833050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K, Wang GC, He YL, Han JF, Ye Q, Qin CF, et al.
Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design. J Biol Chem. 2015;290(6):3198&#x2013;208. doi: 10.1074/jbc.M114.624536 ; PubMed Central PMCID: PMCPMC4318995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.624536</ArticleId><ArticleId IdType="pmc">PMC4318995</ArticleId><ArticleId IdType="pubmed">25492868</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifuente JO, Lee H, Yoder JD, Shingler KL, Carnegie MS, Yoder JL, et al.
Structures of the Procapsid and Mature Virion of Enterovirus 71 Strain 1095. Journal of Virology. 2013;87(13):7637&#x2013;45. doi: 10.1128/JVI.03519-12
</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03519-12</ArticleId><ArticleId IdType="pmc">PMC3700288</ArticleId><ArticleId IdType="pubmed">23637404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulakosky PC, Hughes PR, Wood HA. N-Linked glycosylation of a baculovirus-expressed recombinant glycoprotein in insect larvae and tissue culture cells. Glycobiology. 1998;8(7):741&#x2013;5. .</Citation><ArticleIdList><ArticleId IdType="pubmed">9621115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SA, Lee TY, Ou YY. Incorporating significant amino acid pairs to identify O-linked glycosylation sites on transmembrane proteins and non-transmembrane proteins. BMC Bioinformatics. 2010;11:536
doi: 10.1186/1471-2105-11-536 ; PubMed Central PMCID: PMCPMC2989983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-11-536</ArticleId><ArticleId IdType="pmc">PMC2989983</ArticleId><ArticleId IdType="pubmed">21034461</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa AR, Rodrigues ME, Henriques M, Oliveira R, Azeredo J. Glycosylation: impact, control and improvement during therapeutic protein production. Critical reviews in biotechnology. 2014;34(4):281&#x2013;99. Epub 2013/08/08. doi: 10.3109/07388551.2013.793649 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07388551.2013.793649</ArticleId><ArticleId IdType="pubmed">23919242</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Park JS, Moon JY, Kim KY, Moon HM. The influence of glycosylation on secretion, stability, and immunogenicity of recombinant HBV pre-S antigen synthesized in Saccharomyces cerevisiae. Biochemical and biophysical research communications. 2003;303(2):427&#x2013;32. Epub 2003/03/28. .</Citation><ArticleIdList><ArticleId IdType="pubmed">12659834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossler P. Protein glycosylation control in mammalian cell culture: past precedents and contemporary prospects. Advances in biochemical engineering/biotechnology. 2012;127:187&#x2013;219. Epub 2011/10/22. doi: 10.1007/10_2011_113 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/10_2011_113</ArticleId><ArticleId IdType="pubmed">22015728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkel JP, Jan DC, Butler M, Jamieson JC. Comparisons of the glycosylation of a monoclonal antibody produced under nominally identical cell culture conditions in two different bioreactors. Biotechnology progress. 2000;16(3):462&#x2013;70. Epub 2000/06/03. doi: 10.1021/bp000026u .</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bp000026u</ArticleId><ArticleId IdType="pubmed">10835250</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyakumura M, Walsh R, Thaysen-Andersen M, Kingston NJ, La M, Lu L, et al.
Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity. J Virol. 2015;89(22):11312&#x2013;22. Epub 2015/09/05. doi: 10.1128/JVI.01123-15 ; PubMed Central PMCID: PMCPmc4645671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01123-15</ArticleId><ArticleId IdType="pmc">PMC4645671</ArticleId><ArticleId IdType="pubmed">26339047</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>